Achieving effective pain relief in patients with chronic kidney disease: A review of analgesics in renal failure

Journal of Nephrology

Volumn 24, Issue 1, 2011, Pages 35-40

  Nayak Rao, Shobhana ^a  

^a Bahrain Specialist Hospital   (Bahrain)

Author keywords

Analgesics; Chronic kidney disease; Dialysis; Pain

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CODEINE; DULOXETINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; ISOSORBIDE DINITRATE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; PARACETAMOL;

AGITATION; ALLODYNIA; ANALGESIA; CHRONIC KIDNEY DISEASE; CHRONIC PAIN; CONFUSION; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HALLUCINATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; NARCOLEPSY; NAUSEA; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PRURITUS; RENAL REPLACEMENT THERAPY; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SYMPATHECTOMY; VOMITING;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; HUMANS; KIDNEY FAILURE, CHRONIC; PAIN; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 78651063195     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.1330     Document Type: Review

References (36)

1. Davison SN. Chronic pain in end stage renal disease. Adv Chronic Kidney Dis. 2005;12:326-334.
2. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendation for practice. J Pain Palliat Care Pharmacother. 2007;21:5-16.
3. Merskey H, Bogduk N. Classification of chronic pain. Seattle, WA: International Association for the Study of Pain Press; 1994: 210.
4. Davison SN. Pain in hemodialysis patients. Prevalence, etiology, severity and management. Am J Kidney Dis. 2003;42:1239-1247.
5. Fainsinger R, Davison SN, Brenneis C. A supportive care model for dialysis patients. Palliat Med. 2003;17:81-82.
6. Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL. Pain, sleep disturbances and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:919-925.
7. Bailie GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW. Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription. Kidney Int. 2004;65:2419-2425.
8. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28:497-504.
9. Bunn R, Ashley C. The renal drug handbook. Oxford: Radcliffe Medical Press; 1999.
10. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Clin Pharmacokinet. 1993;24:344-354.
11. Sear JW, Hand CW, Moore RA, et al. Studies on morphine disposition: Influence of renal failure on kinetics of morphine and its metabolites. Br J Anaesth. 1989;62:28-32.
12. Chauvin M, Sandouk P, Scherman JM, et al. Morphine pharmacokinetics in renal failure. Anesthesiology. 1987;66:327-331.
13. Angst MS, Buhrer M, Lotsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine -6- glucoronide action. Anesthesiology. 2000;92:1473-1476.
14. Pauli-Magnus C, Hofmann U, Mikus G, Kuhlmann U, Mettang T. Pharmacokinetics of morphine and its glucoronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1999;14:903-909.
15. Quigtey C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev CD 003447, 2002.
16. Faisinger R, Schoeller T, Boiskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure receiving captopril and hydromorphone. J Palliat Care. 1993;9:53-55.
17. Lee MA, Leng MEF, Tiernan EJJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15:26-34.
18. Durnin C, Hind ID, Wickens MM, Yates DB, Molz KH. Pharmacokinetics of oral immediate release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc. 2001;44:81-82. (Pubitemid 34087721)
19. Vree TB, Verwey-Van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos. 1992;13:445-460.
20. Matzke GR, Cahn GLC, Abraham PA. Codeine dosage in renal failure [letter]. Clin Pharm. 1986;5:15-16.
21. Dole VP, Kreele MJ. Methadone plasma level: sustained by a reservoir of drug. Proc Natl Acad Sci USA. 1973;70:10-15.
22. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980;5:197-205.
23. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983;8:422-446.
24. McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980;28:106-114.
25. Joh J, Sila MK, Bastani B. Nondialyzability of fentanyl with high-efficiency and high -flux membranes [letter]. Anesth Anal. 1998;86:445-451.
26. Bach PH, Berndt WO, Delzell E, et al. A safety assessment of fixed combination of acetaminophen and acetyl salicylic acid co-formulated with caffeine. Ren Fail. 1998;20:749-762.
27. Jankovic SM, Aleksic J, Rakovic S, et al. Non steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding among patients on hemoidlaysis. J Nephrol. 2009;22:502-507.
28. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: Summary and recommendation of the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27:162-165.
29. Buckalew VM. Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Am J Kidney Dis. 1996;28(Suppl1):S7-S13.
30. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiological evidence. Am J Kidney Dis. 1996;28(Suppl1):S14- S19.
31. Melzack R. The Short-Form Mc Gill Pain Questionnaire. Pain. 1987;30:191-197.
32. Barakzoy AS, Moss AH. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol. 2006;17:3198-3203.
33. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J. 2006;32:93-98.
34. Salisbury EM, Game DS, Al-Shakarchi I, et al. Changing practice to improve pain control for renal patients. Postgrad Med J. 2009;83:30-33.
35. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006;82:95-100.
36. Douglas C, Murtagh FEM, Chambers EJ, Howse M, Ellershaw J. Symptom management of the adult patient dying with advanced chronic kidney disease: A review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med. 2009;23:103-110.